Research stack

CJC-1295 + Ipamorelin + AOD-9604 Adipose Cut

Layered GH-axis pulse plus adipose-directed fragment for a research cutting protocol.

Component peptides

The short-acting variant of CJC-1295 — a GHRH(1-29) analog with four amino-acid substitutions for degradation resistance but without the maleimidopropionic-acid moiety that produces albumin binding. Half-life on the order of 30 minutes, in contrast to the DAC version's multi-day exposure.

Ipamorelin

A pentapeptide growth-hormone secretagogue that binds the ghrelin/GHS-R1a receptor, reported as one of the most selective GH-releasers with minimal effect on cortisol or prolactin.

AOD-9604

A 16-amino-acid modified fragment of the C-terminus of human growth hormone (residues 176–191) with an added N-terminal tyrosine, characterised as a lipolytic peptide.

Goal

Layered GH pulse plus adipose-directed fragment for a cutting-phase research protocol.

Peptides

CJC-1295 (no-DAC), Ipamorelin, AOD-9604

Why it works

GHRH + GHRP pulsatile GH release paired with adipose-selective lipolytic signalling from the C-terminal GH fragment biases the somatotropic axis toward fat oxidation without sustained IGF-1 elevation.

How to use

CJC-1295 (no-DAC) — 100 mcg per pulse, 2-3x daily subcutaneous.
Ipamorelin — 100-300 mcg per pulse, co-administered with the GHRH arm.
AOD-9604 — 250-500 mcg once daily subcutaneous, fasted morning.

Last updated: 2026-09-15

Component peptides	CJC-1295 no DAC + Ipamorelin + AOD-9604
Duration reported	12 weeks
Cycle pattern	12 weeks on, 4 weeks off
Difficulty	advanced
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.